Information updates

Approval for COVID-19 vaccine booster doses

Updated 4 January 2022

Since 11 October 2021, Australians who are severely immunocompromised have been able to receive a third COVID-19 vaccine dose to boost their protection against COVID-19 to the highest level.

Since late October 2021 booster doses of COVID-19 vaccines for individuals 18 years and older have been approved. Whilst the original approval was a third booster dose provided at least six months after the completion of a COVID-19 vaccine primary course of two doses, this has been changed in January 2022 to four months in Australia and New Zealand.

Approval of booster doses means that COVID-19 vaccines have been found safe and effective to boost protection for individuals aged 18 years and older through a third booster dose provided after the completion of a COVID-19 vaccine primary course of two doses. The primary course can be any of the COVID-19 vaccines registered for use in Australia or New Zealand. 

People remain fully vaccinated with two doses of approved COVID-19 vaccines and the commencement of booster doses will provide additional protection and peace of mind for Australians and New Zealanders.

Further information: 

https://www.allergy.org.au/about-ascia/info-updates/third-covid-19-vaccine-shot-recommended-for-people-who-are-severely-immunocompromised

https://www.health.gov.au/ministers/the-hon-greg-hunt-mp/media/tga-approval-for-pfizer-covid-19-vaccine-booster-dose-0

 

Mod ASCIA Member
Donate to AIFA
go to NAS website
ASCIA Member Login
ASCIA Update

Information for the community about allergic diseases, immunodeficiencies and other immune diseases.
See latest edition here...
Join our mailing list:

About ASCIA

ASCIA is the peak professional body of clinical immunology and allergy in Australia and New Zealand
ASCIA promotes and advances the study and knowledge of allergy and other immune diseases

Quick Links

About ASCIA

ASCIA is a registered trademark of the Australasian Society of Clinical Immunology and Allergy. All content is subject to copyright for the Australasian Society of Clinical Immunology and Allergy. Read more...

The content for the website is developed and approved by ASCIA Committee and ASCIA Working Party Members. Read more...

Disclaimer I Privacy

The ASCIA website is intended for use by ASCIA members, health professionals and the general public. The content provided is for education, communication and information purposes only and is not intended to replace or constitute medical advice or treatments. Read more...

ASCIA respects your privacy. Read our privacy policy here...

Sponsors | Advertising

ASCIA does not endorse products from sponsoring organisations, nor is it influenced by sponsoring organisations with regard to the content of education programs and websites. 

The ASCIA website does not accept advertising. Any link to a third-party website does not imply any endorsement by ASCIA.

Accreditiation

healthdirect

This website is certified by Health On the Net Foundation. Click to verify. This site complies with the HONcode standard for trustworthy health information: verify here.